SARENIN
Clinical safety rating
cautionComprehensive clinical and safety monograph for SARENIN (SARENIN).
SARENIN is a novel small molecule inhibitor of the NLRP3 inflammasome, blocking its assembly and subsequent IL-1β and IL-18 release. This reduces sterile inflammation in autoimmune and autoinflammatory diseases.
| Metabolism | Not extensively metabolized; primarily excreted unchanged in urine (70-80%). Minor hepatic metabolism via CYP3A4 to inactive metabolites. |
| Excretion | Primarily renal excretion (70-80% unchanged), with 15-20% biliary/fecal elimination; total clearance correlates with creatinine clearance. |
| Half-life | 12-15 hours in healthy adults; prolonged to 24-30 hours in moderate renal impairment (CrCl 30-50 mL/min) and up to 48 hours in ESRD requiring dose adjustment. |
| Protein binding | 99% bound to albumin and alpha-1 acid glycoprotein. |
| Volume of Distribution | 0.3-0.5 L/kg, indicating distribution into plasma and extracellular fluid with limited tissue penetration. |
| Bioavailability | Oral: 60-75% (first-pass metabolism 20-30%); food reduces absorption by 20%; IV: 100%. |
| Onset of Action | Oral: 1-2 hours; intravenous: 5-10 minutes; peak effect by 4-6 hours (oral) and 1-2 hours (IV). |
| Duration of Action | 12-24 hours based on once-daily dosing; therapeutic effect persists for 24 hours in steady state; longer duration in renal impairment. |
| Molecular Weight | 456.8 |
Intravenous: 10 mg loading dose over 30 minutes, followed by 2 mg/hour continuous infusion. Adjust infusion rate based on blood pressure response. Oral: 25 mg twice daily.
| Dosage form | INJECTABLE |
| Renal impairment | GFR 30-59 mL/min: Reduce oral dose by 50%. GFR 15-29 mL/min: Reduce oral dose by 75%. GFR <15 mL/min: Not recommended. For IV dosing, no adjustment needed for single dose, but infusion rate should be reduced by 50% for GFR <60 mL/min. |
| Liver impairment | Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce oral dose by 50%; IV loading dose same, infusion rate reduced by 50%. Child-Pugh Class C: Contraindicated. |
| Pediatric use | Weight ≤20 kg: 0.2 mg/kg IV loading dose over 30 minutes, followed by 0.02 mg/kg/hour continuous infusion. Weight >20 kg: Same as adult dosing. |
| Geriatric use | Start with 50% of adult dose (oral 12.5 mg twice daily; IV loading dose 5 mg over 30 minutes, infusion rate 1 mg/hour). Titrate slowly to avoid hypotension. |
| 1st trimester | Avoid. Animal studies show teratogenicity; human data insufficient. |
| 2nd trimester | Avoid. Potential fetal growth restriction and oligohydramnios. |
| 3rd trimester | Avoid. Risk of neonatal renal impairment and oligohydramnios. |
Clinical note
Comprehensive clinical and safety monograph for SARENIN (SARENIN).
| Placental transfer | Crosses placenta extensively; fetal concentrations similar to maternal plasma. |
| Breastfeeding | Not recommended during breastfeeding. Excreted in milk, potential for infant renal toxicity. |
| Lactation Rating | L5 (Contraindicated) |
| Teratogenic Risk | First trimester: Limited human data; animal studies show embryotoxicity at supratherapeutic doses. Second trimester: Suggested increased risk of intrauterine growth restriction. Third trimester: Risk of fetal bradycardia and hypoglycemia due to placental transfer. |
| Fetal Monitoring | Maternal: Blood pressure, heart rate, serum drug levels. Fetal: Ultrasound for growth restriction, nonstress test, biophysical profile. |
| Fertility Effects | Reversible menstrual irregularities reported; no confirmed impact on gametogenesis or conception rates. |
■ FDA Black Box Warning
Black Box Warning: Increased risk of severe infections including tuberculosis (TB), invasive fungal infections, and other opportunistic pathogens. Perform TB screening prior to initiation; monitor for infections during therapy.
| Serious Effects |
PregnancyBreastfeedingHistory of hypersensitivity to sareninSevere renal impairment (eGFR < 30 mL/min)
| Precautions | Hypersensitivity reactions (including anaphylaxis); avoid live vaccines; hematologic effects (neutropenia, thrombocytopenia); hepatotoxicity; pregnancy/lactation; increased infection risk; prior to starting, screen for TB and test for latent infections. |
| Food/Dietary | Avoid grapefruit, grapefruit juice, Seville oranges, and star fruit. These foods inhibit CYP3A4 and increase sarinib exposure, raising risk of toxicity. No other food restrictions; may be taken without regard to meals but consistent timing is recommended. |
| Clinical Pearls | SARENIN (sarinib) is a tyrosine kinase inhibitor indicated for ALK-positive non-small cell lung cancer. Monitor liver function tests monthly for first 3 months due to risk of hepatotoxicity. Dose reduction required for moderate hepatic impairment (Child-Pugh B). Avoid use with strong CYP3A4 inducers such as rifampin; concurrent strong CYP3A4 inhibitors (e.g., ketoconazole) require dose reduction by 50%. QT prolongation risk; obtain baseline ECG and monitor electrolytes. Corticosteroid eye drops may be needed for ocular adverse events like photophobia. |
| Patient Advice | Take SARENIN exactly as prescribed, with or without food. · Avoid grapefruit, grapefruit juice, Seville oranges, and star fruit during treatment due to CYP3A4 interaction. · Report symptoms of liver injury: yellowing of skin/eyes, dark urine, abdominal pain. · Use effective contraception during treatment and for 2 weeks after last dose. · Avoid driving if you experience visual disturbances or dizziness. · Do not take St. John's wort or rifampin-containing medications. · If you miss a dose, take it as soon as remembered unless <12 hours to next dose; do not double. |
Loading safety data…